Sartorius Stedim Biotech

Consumables underpin solid Q3 2025

23/10/25 -"Sartorius Stedim Biotech reported an estimate-beating Q3 2025. Revenue was up 12.0%, driven almost entirely by the high-margin consumables business. This strong volume growth led to a substantial 420 ..."

PDF page sample
Pages
63
Language
English
Published on
23/10/25
Download
You may also be interested by these reports :
23/10/25
Sartorius Stedim Biotech reported an estimate-beating Q3 2025. Revenue was up 12.0%, driven almost entirely by the high-margin consumables business. ...
22/10/25
Sartorius delivered a robust Q3 2025 performance, beating consensus on both revenue and EBITDA, though slightly missing our EBITDA estimate. Revenue ...
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...
20/10/25
Despite a significant downgrade in our estimates, our strong buy recommendation for Elekta remains unchanged. This is supported by ongoing ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO